Opioid Alternative: New Painkiller & Fewer Side Effects
- A novel drug, SBI-810, may provide significant pain relief without the risks associated with opioid use.
- unlike opioids, which affect numerous cellular pathways, SBI-810 hones in on a particular pain-relief pathway.
- Research published in Cell indicates that SBI-810, tested in mice, effectively reduced pain.
Discover a breakthrough: SBI-810, an experimental non-opioid painkiller, promises effective relief without the risks of addiction and side effects. This innovative drug targets specific pain pathways, offering a safer alternative for acute and chronic pain sufferers.Research reveals SBI-810’s impressive performance in animal studies, outshining existing treatments in managing both surgical and nerve pain. The selective action of SBI-810 on the neurotensin receptor 1 in the brain sets it apart, avoiding the tolerance and constipation often associated with opioids; it is a promising new secondary_keyword. With human trials on the horizon, this could be a game-changer. News Directory 3 reports on the developments in creating safer pain management solutions. Discover what’s next for SBI-810.
Experimental Drug Offers Opioid-Free Pain Relief
A novel drug, SBI-810, may provide significant pain relief without the risks associated with opioid use. This experimental painkiller represents a new class of medications designed to act on specific receptors in the nerves and spinal cord.
unlike opioids, which affect numerous cellular pathways, SBI-810 hones in on a particular pain-relief pathway. This targeted approach avoids the euphoric effects frequently enough linked to opioid addiction.
Research published in Cell indicates that SBI-810, tested in mice, effectively reduced pain. Furthermore, combining it with opioids allowed for lower, more effective doses of the latter.
Ru-Rong Ji, who directs the Duke University Anesthesiology center for Translational Pain Medicine, described the compound as both analgesic and non-opioid.He noted its ability to prevent common opioid-related side effects.
The developers of SBI-810 are moving toward human trials and have secured patents for their finding. The need for non-opioid pain management solutions is critical, given that over 80,000 Americans die annually from drug overdoses, frequently involving opioids, and chronic pain affects a third of the U.S. population.
Researchers suggest SBI-810 could offer a safer option for managing both acute and chronic pain, benefiting individuals recovering from surgery or those with conditions like diabetic nerve pain. The drug targets neurotensin receptor 1 in the brain,activating a specific signal linked to pain relief while avoiding signals that cause adverse effects.
According to Ji, this receptor is found on sensory neurons and in the brain and spinal cord, making it a promising target for pain treatment. In mice,SBI-810 outperformed some existing painkillers in relieving pain from surgical incisions,bone fractures,and nerve injuries. It also reduced signs of discomfort, such as guarding and grimacing.
SBI-810 was compared to oliceridine, a newer opioid used in hospitals, and showed superior performance in certain situations with fewer signs of distress. Unlike morphine, repeated use of SBI-810 did not lead to tolerance. It also surpassed gabapentin, a common nerve pain medication, without causing sedation or memory issues.
The researchers believe the compound’s dual action on both the peripheral and central nervous systems could provide a new balance in pain management, offering effectiveness without the harmful side effects.
“What makes this compound exciting is that it is both analgesic and non-opioid,” said Ru-Rong Ji, anesthesiology and neurobiology researcher at Duke University.
What’s next
The research team plans to move SBI-810 into human clinical trials to further evaluate its safety and efficacy as a non-opioid pain relief option.